Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8286245 | 0.92 | PRKACA (0.45) | PRKACARPS6KB1MTORCYP19A1IRAK4 | |
| SCHEMBL8285554 | 0.81 | ALDH1A3 (0.31) | — | |
| SCHEMBL8284443 | 0.76 | BCHE (0.40) | — | |
| SCHEMBL8285691 | 0.75 | ALDH1A1 (0.34) | PRKACARPS6KB1 | |
| SCHEMBL8286244 | 0.75 | RPS6KB1 (0.42) | RPS6KB1CYP19A1 | |
| SCHEMBL8284441 | 0.69 | TRPC5 (0.42) | — | |
| SCHEMBL8285518 | 0.67 | HRH3 (0.39) | — | |
| SCHEMBL14271721 | 0.66 | — | — | |
| SCHEMBL8284620 | 0.65 | SOS1 (0.41) | RPS6KA5 | |
| SCHEMBL2027616 | 0.64 | PRKACA (0.60) | PRKACARPS6KB1MTORIRAK4RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044073-B2 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-25 | — | — | US | disclosed |
| US-8044073-B2 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-25 | — | — | US | disclosed |
| EP-1697343-B1 | AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2009-07-01 | — | — | EP | disclosed |
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-05-03 | — | — | US | disclosed |
| WO-2005058869-A1 | AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 | PRKACA 4682/4885RPS6KB1 1098/4885NR1H4 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.